TB-500 vs Thymosin Alpha-1: Research Comparison | Peptide Intel Hub

TB-500 is a synthetic peptide based on the active region of thymosin beta-4 (Tβ4). Its proposed research mechanism centres on the actin-binding axis — actin sequestration and downstream effects on cell migration, angiogenesis and tissue remodelling.

Thymosin Alpha-1 (Tα1) is a 28-amino-acid peptide derived from prothymosin-α. Its proposed research mechanism centres on T-cell axis modulation — enhancement of T-cell maturation and downstream immune-response signalling in preclinical models.

TB-500 acts through the thymosin-β4 actin-binding axis rather than a conventional cell-surface receptor.

Thymosin Alpha-1 acts via Toll-like receptor pathways (TLR2 / TLR9) in the immune-axis research literature, with downstream effects on T-cell differentiation and cytokine-response programmes.

TB-500 is a longer peptide fragment with a research half-life supporting less-frequent-than-daily research cadences.

Thymosin Alpha-1 has a short pharmacokinetic half-life (approximately two hours in published research) and is typically used in twice-weekly research cadences in preclinical immune-axis models.

TB-500 is used in research models of cell migration, wound healing, angiogenesis and tissue remodelling.

Thymosin Alpha-1 is used in research models of immune-response modulation, T-cell axis studies, viral-response research and adjuvant immune-axis work.

Both TB-500 and Thymosin Alpha-1 should only be sourced from suppliers that use independent third-party verification — Janoshik Analytical is the default verifier, with orthogonal independent laboratories used when batch chemistry calls for confirmation by a second method. Minimum release specification is ≥99.0% HPLC main-peak purity with matching mass-spectrometry molecular weight and water content within the published specification for the compound.

Batch COAs for both compounds should be published by the supplier so a researcher can audit the analytical detail. The /trust/how-to-read-a-coa reference walks through every field on a modern COA.

Both compounds ship lyophilised under nitrogen. Hold the unopened vial at 2–8 °C; freeze at −20 °C for long-term storage. Reconstitution with bacteriostatic water (0.9% benzyl alcohol) supports a two-month (60-day) in-use stability window under refrigeration for both compounds.

Aliquot before any freeze. The single most common cause of measurable potency loss in research peptides is repeat freeze-thaw cycling — both TB-500 and Thymosin Alpha-1 benefit from single-thaw aliquot workflows. Vortex gently, never shake aggressively, and keep reconstituted vials away from direct light. The /research/compound-storage-guide reference covers the per-compound stability windows in detail.

Researchers choose TB-500 when the protocol targets the tissue-repair / actin-binding axis — cell migration, wound-healing, angiogenesis. Researchers choose Thymosin Alpha-1 when the protocol targets the immunomodulatory / T-cell axis. The two are complementary rather than substitutable — comparator studies sometimes include both to characterise thymosin-family effects across two independent research axes.

For multi-compound comparator studies, reputable suppliers can often reserve matched-batch inventory of both TB-500 and Thymosin Alpha-1 against a project timeline so the experimental panel is sourced under a single analytical specification window.

Thymosin beta-4 (Tβ4) is a small, 5-kDa protein that plays a diverse range of roles within the body, including functioning as an actin monomer sequestering protein, an anti-inflammatory agent, and an inhibitor of bone marrow stem cell proliferation (PMID 12852258). It is the predominant β-thymosin in mammalian cells, encoded by the X-linked TMSB4x gene, and acts as a multifunctional regulator of cellular homeostasis (PMID 41570941). The flexible, largely unfolded structure of Tβ4 may enable it to recognize various molecular targets, which could explain its wide array of attributed functions (PMID 12852258). This flexibility might facilitate its unique integrative function, potentially linking the actin cytoskeleton to important immune and cell growth-signaling cascades (PMID 12852258). Research into Tβ4's expression levels in human organs from fetal development to different ages after birth suggests significant details about its potential molecular role during human development, helping to resolve the 'β-thymosin enigma' (PMID 38994967, PMID 17495248).

Initially regarded primarily as an actin-sequestering molecule, Tβ4 and its N-terminal metabolite N-acetyl-Ser-Asp-Lys-Pro (Ac-SDKP) are now recognized as dynamic mediators of injury and repair in various systems (PMID 41570941). The 'β-thymosin enigma' refers to the complex pleiotropic effects of β-thymosins in cells, which may arise from both direct and indirect impacts on the actin cytoskeleton, as well as modulation of signaling pathways affecting the cytoskeleton and diverse cell functions (PMID 17495248). Tβ4's ability to inhibit the polymerization of G-actin into F-actin is a key mechanism for some of its effects (PMID 29508629, PMID 31877278). These fundamental properties contribute to its involvement in processes like anti-inflammation, wound healing, angiogenesis, and cancer progression (PMID 27450733).

Recent research has identified Thymosin beta-4 (Tβ4) as a potential intervention target for Alzheimer's disease (AD). A study using cerebral organoids, derived from induced pluripotent stem cells (iPSCs) with familial AD-associated mutations, found a significant decrease in the expression of the gene encoding Tβ4 (TMSB4X) in both fAD organoid neurons and AD patients' excitatory neurons (PMID 40816274). Remarkably, treatment with Tβ4 in these fAD organoids rescued neurodevelopmental deficits and reduced β-amyloid (Aβ) production, indicating its potential as a neuroprotective factor (PMID 40816274). Furthermore, beneficial effects of Tβ4 were also observed in 5xfAD model mice, highlighting its potential for disease intervention in neurodegenerative conditions (PMID 40816274).

Beyond neuroprotection, Tβ4 demonstrates promise in organ repair and regeneration. In preclinical models of cardiac ischemic injury, Tβ4 treatment reduces infarct volume and preserves cardiac function (PMID 27450736). These benefits partly stem from decreased infarct size, but also from its antifibrotic and proangiogenic activities (PMID 27450736). Injected or transgenic Tβ4 has been shown to increase blood vessel growth in large and small animal models (PMID 27450736). In a mouse embryo model, Tβ4 was expressed in the developing heart and promoted cardiac cell migration and survival (PMID 36709593). In adult animals, systemic injection of Tβ4 enhanced myocyte survival and improved cardiac function after coronary artery ligation, and also altered the morphology of the adult epicardium to resemble an embryonic state, reactivating an embryonic program (PMID 36709593). This led to an increased number of cardiac vessels and alteration of gene expression profiles typical of the embryonic state (PMID 36709593). Additionally, Tβ4 was found to activate epicardial progenitors, independently of hypoxic injury (PMID 36709593). These findings suggest Tβ4 may help reverse aging processes and accelerate organ regeneration (PMID 36709593).

Thymosin beta-4 (Tβ4) exhibits significant anti-inflammatory properties. In sepsis, a life-threatening organ dysfunction, Tβ4 is an actin-binding protein that improves mortality when administered intravenously to septic rats (PMID 29508629). It decreases inflammatory mediators, lowers reactive oxygen species, and up-regulates anti-oxidative, anti-inflammatory, and anti-apoptotic enzymes (PMID 29508629). Sepsis results in measurable levels of F-actin in circulation and a decreased concentration of Tβ4; it is speculated that Tβ4 decreases mortality in sepsis through actin regulation and its other anti-inflammatory effects (PMID 29508629).

Furthermore, Tβ4 has shown potential in preserving barrier integrity. In an in vitro human blood-brain barrier (BBB) model using hCMEC/D3 human cerebral endothelial cells, Tβ4 attenuated PrP(106-126)-induced dysfunction (PMID 31877278). Tβ4 increased the expression of tight junction proteins and improved PrP(106-126)-induced vascular permeability dysfunction (PMID 31877278). These results suggest Tβ4 may play a critical role in barrier stabilization and potentially prevent neurodegenerative diseases caused by prion-induced BBB dysfunction (PMID 31877278).

Thymosin beta-4 (Tβ4) is recognized as an emerging therapeutic candidate for kidney diseases (PMID 41570941). It is a multifunctional regulator involved in cellular homeostasis, and current evidence on the Tβ4-Ac-SDKP axis maps its intra- and extracellular mechanisms, signaling pathways, and cell-type and spatial expression across glomerular and tubular compartments (PMID 41570941). Tβ4 has demonstrated renoprotective efficacy, including cytoprotection, anti-inflammatory, and antifibrotic actions, across models of acute and chronic kidney injury (PMID 41570941). However, the evidence also suggests bidirectional effects on fibrosis and model-dependent mechanisms, indicating a complex role that requires further validation in clinically relevant models and comprehensive safety assessments (PMID 41570941).

In liver health, the role of Tβ4, particularly in liver fibrosis, is complex and appears to be context-dependent. Liver fibrosis, often characterized by the activation of hepatic stellate cells (HSCs), is a major component of chronic liver disease (PMID 27450733, PMID 26006229). Exogenous Tβ4 peptide treatment inhibits the proliferation and migration of activated HSCs and reduces liver fibrosis, indicating an antifibrotic action (PMID 27450733, PMID 26006229). Conversely, endogenously expressed Tβ4 in activated HSCs has been shown to promote HSC activation (PMID 27450733). Although its precise role is not fully elucidated, Tβ4 is associated with HSC activation, suggesting it could be a therapeutic target for liver diseases (PMID 27450733, PMID 26006229).

Thymosin alpha-1 (Tα1) is a synthetic polypeptide (PMID 11381492) and a naturally occurring peptide hormone produced by the thymus, crucial for maintaining organism homeostasis (PMID 30063864, PMID 41373628). It possesses potent immunomodulatory, anti-inflammatory, and antioxidant properties (PMID 41373628). Tα1 is thought to modulate the immune system by augmenting T-cell function and stimulating the differentiation of thymocytes or converting them into active T cells (PMID 11381492, PMID 41373628). Its primary role involves helping to restore immune function by stimulating T-cell differentiation, enhancing thymic output, and modulating the activity of dendritic cells and macrophages (PMID 41373628).

Tα1 is rapidly absorbed, achieving peak serum concentrations within two hours, and blood levels return to baseline within 24 hours, with a serum half-life of approximately 2 hours (PMID 11381492). Many clinical trials have investigated Tα1's effects in patients with cancer, infectious diseases, and as a vaccine enhancer (PMID 30063864). Evidence suggests that diseases characterized by deregulation of immune and/or inflammatory responses, such as B hepatitis, psoriatic arthritis, multiple sclerosis, and sepsis, are associated with significantly lower serum Tα1 levels than those in healthy individuals (PMID 30063864). This indicates Tα1's role as a regulator of immunity, tolerance, and inflammation (PMID 30063864). Low serum Tα1 levels may be predictive or associated with various pathological conditions (PMID 30063864).

Thymosin alpha-1 (Tα1) has been widely studied for its efficacy in various viral infections, particularly chronic hepatitis B (CHB) and hepatitis C. In CHB, Tα1 monotherapy has shown effectiveness in suppressing viral replication compared to untreated controls or conventional interferon (PMID 25640173). Combination therapy of Tα1 with either lamivudine or IFN-α has demonstrated improved effects on HBV DNA suppression and HBeAg seroconversion (PMID 25640173). For hepatitis B, one study found HBV DNA clearance at six months in 9 of 17 patients receiving Tα1, compared with 10 of 16 patients treated with interferon alfa-2b (IFN-α2b) and 4 of 15 historical controls (human study, PMID 11381492). Another open-label trial observed HBV DNA clearance in 53% of patients at six months (human study, PMID 11381492). In hepatitis C, combination Tα1 and IFN-α2b therapy showed promising results, with one trial reporting a normal serum alanine aminotransferase (ALT) level at six months in 71% of patients receiving combination therapy versus 35% with IFN-α2b alone (human study, PMID 11381492). HIV-1 infected patients undergoing antiretroviral therapy, who often experience immunological unresponsiveness and persistent inflammatory conditions, may also benefit from Tα1 due to its ability to restore immune system homeostasis (PMID 28106477).

Tα1 is also being investigated for its role in mitigating the effects of aging on the immune system. Aging leads to immune decline, primarily due to thymic involution and reduced T-cell production, increasing susceptibility to age-related diseases (PMID 41373628). Preclinical and clinical studies indicate that Tα1 can improve vaccine response in the elderly and mitigate immunosenescence by stimulating T-cell differentiation and enhancing thymic output (PMID 41373628). A systematic review and meta-analysis on moderate to critical COVID-19 patients found that Tα1 therapy significantly lowered mortality (RR 0.59; 95% CI 0.37-0.93, p = 0.02, I2 = 84%) but did not significantly affect the need for mechanical ventilation or hospital length of stay (human study, PMID 37845598). The benefits on mortality were significantly affected by sample size and sex (human study, PMID 37845598).

Thymosin alpha-1 (Tα1) plays a significant role as an immune modulator in conditions like sepsis, where host immune response to infection can lead to life-threatening organ dysfunction (PMID 30063866). In clinical studies, Tα1 treatment, both alone and in combination with anti-inflammatory agents, has been shown to reduce the mortality rate of sepsis, improve the expression of HLA-DR on monocytes, and diminish the incidence of secondary infection (human studies, PMID 30063866). These findings suggest Tα1 is a promising alternative adjuvant therapy for sepsis, particularly for immunosuppressed individuals (PMID 30063866).

For severe acute pancreatitis (SAP), characterized by immune and inflammatory disorders, Tα1 has demonstrated efficacy in meta-analyses (PMID 40599771). Five randomized controlled trials involving 706 SAP patients indicated that Tα1 increased percentages of CD4+ cells and improved the CD4+/CD8+ ratio (human study, PMID 40599771). Lower doses of Tα1 significantly reduced C-reactive protein (CRP) levels (human study, PMID 40599771). Furthermore, immunomodulatory therapy with Tα1 significantly reduced the overall incidence of extrapancreatic infections in SAP patients, particularly blood and abdominal infections (human study, PMID 40599771). Although Tα1 did not significantly reduce hospital stay, it did reduce the APACHE II score, indicating its potential to regulate immune cell balance and alleviate immune suppression in SAP patients (human study, PMID 40599771).

Thymosin alpha-1 (Tα1) has been investigated for its curative effects in patients experiencing acute exacerbation of chronic obstructive pulmonary disease (AECOPD). A systematic review and meta-analysis of thirty-nine randomized controlled trials, involving a total of 3,329 patients, compared Tα1 plus routine treatment with routine treatment alone (human study, PMID 39648386). The results showed that Tα1 therapy significantly improved forced expiratory volume in 1 second (MD = 0.29), the ratio of forced expiratory volume in the first second to forced vital capacity (MD = 6.24), and increased the arterial partial pressure of oxygen (MD = 7.24) (human study, PMID 39648386). It also lowered the arterial partial pressure of carbon dioxide (MD = -5.85) and shortened the length of hospital stay (MD = -5.39) (human study, PMID 39648386).

In terms of immune function, Tα1 treatment significantly raised the level of CD4+ T lymphocytes count (MD = 7.54) and the ratio of CD4+/CD8+ (MD = 0.40), while decreasing the level of CD8+ T lymphocytes count (MD = -2.74) (human study, PMID 39648386). These findings indicate that Tα1 can significantly boost immune function, improve pulmonary function, and enhance arterial blood gas in AECOPD patients compared to routine treatment alone (human study, PMID 39648386). However, the review concluded that more high-quality randomized controlled trials are needed to further confirm the efficacy of Thymosin alpha 1 in this context (PMID 39648386).

• Thymosin β4 and β10 Expression in Human Organs during Development: A Review. — Cells (2024). PMID 38994967
• Thymosin beta 4 as an Alzheimer disease intervention target identified using human brain organoids. — Stem cell reports (2025). PMID 40816274
• Thymosin beta-4 denotes new directions towards developing prosperous anti-aging regenerative therapies. — International immunopharmacology (2023). PMID 36709593
• Thymosin beta 4 interactions. — Vitamins and hormones (2003). PMID 12852258
• Thymosin beta 4 regulation of actin in sepsis. — Expert opinion on biological therapy (2018). PMID 29508629
• Thymosin beta 4: An emerging therapeutic candidate for kidney diseases. — Peptides (2026). PMID 41570941
• Thymosin Beta 4 Is a Potential Regulator of Hepatic Stellate Cells. — Vitamins and hormones (2016). PMID 27450733
• Cardioprotection by Thymosin Beta 4. — Vitamins and hormones (2016). PMID 27450736
• The beta-thymosin enigma. — Annals of the New York Academy of Sciences (2007). PMID 17495248
• Thymosin beta 4 attenuates PrP(106-126)-induced human brain endothelial cells dysfunction. — European journal of pharmacology (2020). PMID 31877278
• Potential role of thymosin Beta 4 in liver fibrosis. — International journal of molecular sciences (2015). PMID 26006229
• Thymosin alpha-1. — American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists (2001). PMID 11381492
• Aging and Thymosin Alpha-1. — International journal of molecular sciences (2025). PMID 41373628
• Thymosin alpha 1 treatment for patients with sepsis. — Expert opinion on biological therapy (2018). PMID 30063866
• Thymosin Alpha 1 Plus Routine Treatment for the Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis. — Journal of the College of Physicians and Surgeons--Pakistan : JCPSP (2024). PMID 39648386
• Serum thymosin alpha 1 levels in normal and pathological conditions. — Expert opinion on biological therapy (2018). PMID 30063864
• Thymosin alpha 1 alleviates inflammation and prevents infection in patients with severe acute pancreatitis through immune regulation: a systematic review and meta-analysis. — Frontiers in immunology (2025). PMID 40599771
• Thymosin alpha 1 and HIV-1: recent advances and future perspectives. — Future microbiology (2017). PMID 28106477
• The efficacy of thymosin alpha-1 therapy in moderate to critical COVID-19 patients: a systematic review, meta-analysis, and meta-regression. — Inflammopharmacology (2023). PMID 37845598
• Thymosin alpha-1 treatment in chronic hepatitis B. — Expert opinion on biological therapy (2015). PMID 25640173

Both TB-500 and Thymosin Alpha-1 are supplied strictly for in-vitro and preclinical research use. They are not medicines, are not approved for human consumption in Spain, the United Kingdom, the European Union or the United States, and are not dispensed against a prescription. The research-use declaration ships with every package alongside the independent third-party COA.

Comparison pages on Peptide Intel Hub exist for laboratory-research reference. Nothing on this page constitutes a recommendation for human use of either compound.